Identification
- Generic Name
- Fursultiamine
- DrugBank Accession Number
- DB08966
- Background
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Fursultiamine (DB08966)
- Weight
- Average: 398.543
Monoisotopic: 398.144632098 - Chemical Formula
- C17H26N4O3S2
- Synonyms
- Fursultiamina
- Fursultiamine
- Fursultiaminum
- Thiamin tetrahydrofurfuryl disulfide
- Thiamine tetrahydrofurfuryl disulfide
- TTFD
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Fursultiamine hydrochloride T3557LWB27 2105-43-3 OPGOLNDOMSBSCW-CLNHMMGSSA-N - International/Other Brands
- Adventan / Alinamin F / Diteftin / Judolor / Linamin
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ALINAMIN EX PLUS Fursultiamine hydrochloride (36.39 MG) + Cyanocobalamin (500 MCG) + Calcium pantothenate (10 MG) + Pyridoxine hydrochloride (33.33 MG) + Vitamin E (33.33 MG) Tablet, sugar coated Oral บริษัท ทาเคดา (ประเทศไทย) จำกัด 2014-04-02 Not applicable Thailand 
ALINAMIN-F ODORLESS TABLET Fursultiamine (50 mg) + Riboflavin (5 mg) Tablet, sugar coated Oral LUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED 1991-06-21 Not applicable Singapore Aronamin Gold Fursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1) Tablet, film coated Oral OASIS TRADING 2018-11-20 Not applicable US 
NEVRAMIN TABLET Fursultiamine (50 mg) + Cyanocobalamin (250 mcg) + Pyridoxine hydrochloride (250 mg) Tablet, sugar coated Oral LUEN WAH MEDICAL COMPANY (SINGAPORE) PRIVATE LIMITED 1991-06-21 Not applicable Singapore Nevramin Tablets Fursultiamine (50 mg) + Cyanocobalamin (250 mg) + Pyridoxine hydrochloride (250 mg) Tablet Oral LUEN WAH MEDICAL CO. SDN. BHD. 2020-09-08 Not applicable Malaysia 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aronamin Gold Fursultiamine (50 mg/1) + Ascorbic acid (70 mg/1) + Hydroxocobalamin acetate (5.22 ug/1) + Riboflavin tetrabutyrate (2.5 mg/1) + alpha-Tocopherol acetate (20 mg/1) Tablet, film coated Oral OASIS TRADING 2018-11-20 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hydropyrimidines. These are compounds containing a hydrogenated pyrimidine ring (i.e. containing less than the maximum number of double bonds.).
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Hydropyrimidines
- Alternative Parents
- Imidolactams / Tetrahydrofurans / Tertiary carboxylic acid amides / Heteroaromatic compounds / Organic disulfides / Sulfenyl compounds / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Primary alcohols show 5 more
- Substituents
- Alcohol / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Dialkyl ether / Ether / Heteroaromatic compound / Hydrocarbon derivative show 15 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 05J61265PX
- CAS number
- 804-30-8
- InChI Key
- JTLXCMOFVBXEKD-FOWTUZBSSA-N
- InChI
- InChI=1S/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+
- IUPAC Name
- N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(2E)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent-2-en-2-yl]formamide
- SMILES
- C\C(N(CC1=C(N)N=C(C)N=C1)C=O)=C(\CCO)SSCC1CCCO1
References
- Synthesis Reference
U.S. Patent 3,016,380.
- General References
- Kobayashi T, Notoya K, Nakamura A, Akimoto K: Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res. 2005 Jun;54(6):249-55. [Article]
- External Links
- PubChem Compound
- 3002119
- PubChem Substance
- 310264929
- ChemSpider
- 2273321
- 4604
- ChEBI
- 135636
- ChEMBL
- CHEMBL1740659
- Wikipedia
- Fursultiamine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Supportive Care Eczema; Contact, Allergic 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, sugar coated Oral Tablet, sugar coated Oral 50 mg Tablet, film coated Oral Injection Tablet, sugar coated Oral 250 mcg Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 132 U.S. Patent 3,016,380. - Predicted Properties
Property Value Source Water Solubility 0.123 mg/mL ALOGPS logP 1.38 ALOGPS logP -0.47 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 15.9 Chemaxon pKa (Strongest Basic) 6.26 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 101.57 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 111.54 m3·mol-1 Chemaxon Polarizability 42.81 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 09, 2014 15:23 / Updated at February 21, 2021 18:52